Over the course of my career in healthcare, I’ve been fortunate to serve in a leadership role through four IPOs and even more financing rounds. All told, I’ve raised well over $1.5 billion in capital. That means I’ve spent a lot of time thinking about dilution. By Joshua Brumm, CEO of Dyne Therapeutics, as partRead More »
The post Beyond The Balance Sheet: Thinking Broadly About Dilution In Building A Transformative Biotech appeared first on Atlas Venture.